fundamental difference between truncal mutations and branch mutations. In particular, branch mutations were characterized by a high percentage of C>T transitions, specifically at CpG dinucleotides, and by a lower percentage of A>G transitions when compared to truncal mutations, suggesting that specific mechanisms may underlie the later development of genomic heterogeneity in CCRCC. Further elucidation of CCRCC mutational signatures will hopefully facilitate the identification of druggable targets to alter tumor evolution or to prevent or slow the development of drug resistance.
Treating genomic heterogeneity
How do you develop a targeted therapeutic approach to a tumor with substantial genomic heterogeneity? One approach is to target truncal mutations 6 , such as those in VHL, which were found in every sample and are known to be an early event in CCRCC tumorigenesis. Studies of the VHL gene pathway over the past 20 years have provided the foundation for the development of seven targeted approaches that have been approved by the US Food and Drug Administration (FDA) for treating individuals with advanced disease. Current targeted therapeutic approaches for the VHL-HIF pathway in CCRCC revolve around targeting downstream HIF (hypoxia-inducible factor) pathway genes 7 , such as the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors. So far, this approach has been only partially successful, possibly owing to the fact that only a small portion of the HIF pathway is targeted. A more effective strategy might involve adopting a more global approach or developing combinatorial approaches to target the VHL-HIF pathway 8 . The increased availability of next-generation sequencing provides the opportunity for mutational analysis of
Assessing cancer mutations
Although tumor heterogeneity, assessed by mutation or copy number analysis, has previously been observed in a number of epithelial cancers, including breast, pancreatic and ovarian cancers [3] [4] [5] , the study by Gerlinger et al. 2 highlights the variability in mutational signatures that can occur during the development of large renal tumors. VHL gene mutation, combined with chromosome 3p loss, was universally found in each sample from every tumor and was considered to be a 'truncal' mutation (present early in the genomic phylogenetic tree). Truncal mutation of the chromatinremodeling gene PBRM1 was also found in a subset of tumors. Conversely, other driver mutationsincluding alterations in the chromatin-remodeling genes SETD2, BAP1 and KDM5C, the TP53 gene and genes in the phosphoinositide 3-kinase (PI3K)-mTOR pathway (PTEN, PIK3CA, TSC2 and MTOR)-were found to be present only in segments of the tumor and were labeled 'branch' mutations. In general, each assessed portion of tumor was found to have a unique spectrum of branch mutations. Thus, M-seq analysis provides a view of the genomic architecture of a tumor that is not possible to ascertain from analysis of a single portion of a tumor.
Although The Cancer Genome Atlas clear cell kidney carcinoma (TCGA KIRC) singlesample mutational screen identified the same spectrum of driver mutations as the M-seq analysis, prevalence was considerably higher with M-seq for TP53 mutations and PI3K-mTOR pathway mutations (5% and 18% versus 40% and 60%, respectively). Gerlinger et al. 2 also found that, as more areas were sampled, more heterogeneity was identified, suggesting that even this study underestimates the true extent of genomic heterogeneity in CCRCC.
Another new finding of this study was the Kidney cancer affects nearly 300,000 individuals worldwide each year and is responsible for nearly 100,000 deaths annually. Clear cell kidney cancer, which represents 75% of cases, occurs in both a sporadic (non-hereditary) and a hereditary form. Mutations in the VHL gene, located on the short arm of chromosome 3, cause the inherited form associated with von Hippel-Lindau disease. VHL is also inactivated by mutation or hypermethylation in over 90% of sporadic clear cell kidney cancers 1 . The fact that clear cell kidney cancers are slow growing, likely taking decades to reach 5 cm in size, and the observation that biallelic inactivation of the VHL gene is a very early event in the genesis of clear cell kidney cancer make this malignancy an ideal model to study the genomic architecture and evolution of cancer. On page 225 of this issue, Charles Swanton and colleagues 2 report the application of multi-region exome sequencing (M-seq) to investigate intratumoral heterogeneity in a collection of large (7-to 13-cm) CCRCCs. Notably, many of the mutations perceived to be cancer drivers were found to be present in only a segment of each tumor, and genesis of the later mutations observed in the different regions appeared to be fundamentally different from mechanisms responsible for the early genetic events. This work raises profound questions concerning the genetic landscape of cancer and how tumor heterogeneity may affect, and possibly confound, targeted therapeutic interventions. from studies of the mammalian XY and bird ZW sex-chromosome pairs, but both systems evolved hundreds of millions of years ago, so the trail has gone rather cold. On page 253 of this issue, Songlin Chen and colleagues 1 report sequencing of the Chinese half-smooth tongue sole, Cynoglossus semilaevis. The decision to study this flatfish species is appropriate, as this fish is rather flexible about sex. It boasts 30 million-year-old Z and Y sex chromosomes (ZZ in males and ZW in females, as in birds) but also has a mechanism for sex reversal, with a high-temperature override that produces fertile ZW pseudomales. This separates sex Sex chromosomes are nothing but trouble.
Once an autosome pair acquires a sexdetermining gene, degradation of a sex-specific Y or W chromosome sets in, leading to pairing difficulties, the 'peril of hemizygosity' and unequal gene dosage between the sexes. Our understanding of how sex chromosomes evolve and how gene expression is modified to mitigate the consequent problems comes mostly multiple primary and metastatic biopsies to be performed either initially or after a VHL-based therapy (Fig. 1) . This sequencing may identify multiple mutations associated with alternative targeted therapies that could be selected depending on the portion of the tumor containing each mutation, their presence at more aggressive metastatic sites or their increased presence after initial therapy.
Targeting CCRCC metabolism
Mutation of chromatin-remodeling genes has been a consistent finding in single-sample analyses of CCRCC [9] [10] [11] , and the study by Gerlinger et al. 2 emphasizes their importance by demonstrating a degree of parallel evolution occurring in the same chromatin-remodeling genes, including SETD2, BAP1, KDM5C and PBRM1.
Integrative analyses comparing patient outcome and SETD2 and BAP1 mutation have shown a correlation with decreased survival in patients with CCRCC 12, 13 . In addition, an altered metabolic pattern, consistent with a Warburg shift to aerobic glycolysis with decreased oxidative phosphorylation and glutamine-dependent reductive carboxylation 14 , was identified in the TCGA CCRCC study 12 in patients with advanced tumors and low survival rates. If multiple biopsies are taken for sequence analysis, metabolic analysis could also be performed on the same samples to both correlate metabolic changes with the mutational spectrum and potentially select a targeted therapy. It is possible that gain of additional driver mutations and alteration of metabolism are fundamental to the development of advanced CCRCC and that targeting the metabolic basis of CCRCC 15 could provide a foundation for the development of effective forms of therapy for this disease. In summary, the findings of Swanton and colleagues have profound implications for understanding the genomic architecture and evolution of CCRCC-and potentially other forms of cancerand for the development of therapeutic approaches for CCRCC as well as other malignancies. Figure 1 CCRCC is characterized by substantial genomic heterogeneity during tumor development. Potential approaches to identify targeted therapy could involve multiregion exome sequencing (M-seq) of multiple primary tumor foci to identify common driver mutations. Alternatively or in addition, tumors from metastatic sites could undergo sequence analysis to identify driver mutations essential for the development of metastases.
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The epigenetic sole of sex and dosage compensation Jennifer A Marshall Graves sex chromosomes in mammals, birds, reptiles and fish represent many independent evolutionary events, but there is spectacular convergence and stunning parallels. a new study details the early stages of Zw differentiation and sex determination in a flatfish and the establishment of dosage compensation and sex reversal by epigenetic mechanisms including dna methylation.
Jennifer A. Marshall Graves is at the La Trobe Institute of Molecular Science, Melbourne, Victoria, Australia. e-mail: j.graves@latrobe.edu.au determination from sex chromosomes, permitting identification of the genes and modifications that determine sex and dosage. Chen et al. 1 sequenced the small (477-Mb) genome of a ZZ male and a ZW female and anchored contigs onto the 20 autosomes and Z and W sex chromosomes using microsatellite markers. Z-chromosome linkage was confirmed by quantitative PCR, and W-chromosome sequence was deduced by subtraction and assembled according to the order of homologs on the Z chromosome. Transcriptome sequences were generated to aid in gene annotation and to measure the npg
